Last reviewed · How we verify
NCT06557057
Impact of Aromatase Inhibitor Therapy on Glucose Homeostasis and Diabetes Risk
trial testing Non-Interventional Study in HER2-Positive Breast Carcinoma in 66 participants. Currently enrolling.
1 December 2026
Quick facts
| Lead sponsor | Mayo Clinic |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 66 |
| Start date | 16 November 2023 |
| Primary completion | 1 December 2026 |
| Estimated completion | 1 December 2026 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Non-Interventional Study (non-interventional-study) — full drug profile →
Conditions studied
- HER2-Positive Breast Carcinoma — all drugs for HER2-Positive Breast Carcinoma →
Sponsor
Mayo Clinic
Who can join
Eligibility, female only, with HER2-Positive Breast Carcinoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study assesses the effect of hormone directed treatment for breast cancer on glucose metabolism.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06557057
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Non-Interventional Study
Trials testing the same drug.
- NCT07221656 — Evaluation of Prolonged Asparaginase Activity Levels After Calaspargase Pegol Administration · not yet recruiting
- NCT07412002 — Quality of End-of-Life Care for Children With Cancer · not yet recruiting
- NCT06607874 — Self-Collection for Cervical Cancer Screening and HPV Vaccination for Cancer Prevention Among Women in Emergency Care in · not yet recruiting
- NCT06630338 — Use of Shear Wave Elastography for Intraoperative Brain and Tumor Stiffness Measurements · not yet recruiting
- NCT07235501 — Kinetic Analysis of Immune Cells in Blood and Chronic Graft-Versus-Host Disease-Affected Tissues After Allogeneic Hemato · not yet recruiting
Other recruiting trials for HER2-Positive Breast Carcinoma
Currently open trials in the same condition.
- NCT05710328 — Testing the Role of FDG-PET/CT to Predict Response to Therapy Prior to Surgery for HER2-positive Breast Cancer, The DIRE · Phase 2 · active not recruiting
- NCT04704661 — Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expre · Phase 1 · recruiting
- NCT04550494 — Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations · Phase 2 · recruiting
- NCT04517838 — Immune Response to Anti-HER2 Therapies in Patients With HER2-Positive Stage I-IV Breast Cancer · recruiting
- NCT03179904 — TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer · Phase 2 · active not recruiting
Other Mayo Clinic trials
Trials by the same sponsor.
- NCT07126548 — A Point of Prostate Cancer Diagnosis Virtual Reality Assistant Intervention in Supporting Newly Diagnosed Black Men · NA · not yet recruiting
- NCT07221656 — Evaluation of Prolonged Asparaginase Activity Levels After Calaspargase Pegol Administration · not yet recruiting
- NCT06891001 — The Utilization of a Shoe Insert on Individuals With Unilateral Greater Trochanteric Pain Syndrome on Single Leg Stance, · NA · not yet recruiting
- NCT07169799 — Impact of Cryotherapy Spray (Tru-Freeze) for the Eradication of Gastric Antral Vascular Ectasia (ICE-GAVE) · NA · recruiting
- NCT07086183 — Perioperative Risk in Patients on Chronic Aspirin Undergoing Craniotomy · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06557057 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Mayo Clinic
- Last refreshed: 31 March 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06557057.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing